Visser J H, Wessels G, Hesseling P B, Louw I, Oberholster E, Mansvelt E P
Department of Paediatrics and Child Health, Tygerberg Hospital and University of Stellenbosch, Tygerberg, South Africa.
Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91. doi: 10.1080/08880010151114804.
The product of the percentage blasts on the bone marrow aspirate (BMA) and the biopsy cellularity has been termed the "absolute blast index aspirate" (ABI-aspirate) and is used to measure disease response on day 7 of induction therapy. The authors compared the event-free survival (EFS) in high-risk and standard-risk patients as identified by the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy. Both indices identified high-risk cases. EFS of patients categorized as high-risk by these 2 methods and the high-risk criteria used by the authors' service (WCC of > 20 x 10(9)/L, age < 2 and > 8 years and a peripheral blood blast count of > 1.0 x 10(9)/L on day 8 of induction) did not differ. There was concordance between patients identified as high risk by all 3 methods. The results confirmed the prognostic value of the ABI-aspirate and the BMA percentage blasts on day 14 of induction therapy, but these methods were not superior to the high-risk criteria currently in use.
骨髓穿刺液（BMA）中原始细胞百分比与活检细胞密度的乘积被称为“绝对原始细胞指数穿刺液”（ABI-穿刺液），用于衡量诱导治疗第7天的疾病反应。作者比较了根据ABI-穿刺液和诱导治疗第14天BMA原始细胞百分比确定的高危和标准风险患者的无事件生存期（EFS）。这两个指标都能识别高危病例。通过这两种方法分类为高危的患者以及作者所在科室使用的高危标准（诱导第8天白细胞计数>20×10⁹/L、年龄<2岁和>8岁且外周血原始细胞计数>1.0×10⁹/L）的EFS没有差异。所有三种方法确定为高危的患者之间存在一致性。结果证实了诱导治疗第14天ABI-穿刺液和BMA原始细胞百分比的预后价值，但这些方法并不优于目前使用的高危标准。
